Quest Partners LLC Raises Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Quest Partners LLC increased its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 898.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,434 shares of the company’s stock after purchasing an additional 3,090 shares during the period. Quest Partners LLC’s holdings in Dyne Therapeutics were worth $123,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Seven Eight Capital LP boosted its stake in shares of Dyne Therapeutics by 195.7% during the 2nd quarter. Seven Eight Capital LP now owns 53,739 shares of the company’s stock worth $1,896,000 after purchasing an additional 35,568 shares during the last quarter. State of New Jersey Common Pension Fund D purchased a new position in shares of Dyne Therapeutics during the third quarter valued at approximately $1,588,000. Mutual of America Capital Management LLC acquired a new stake in Dyne Therapeutics during the second quarter worth approximately $1,724,000. Vanguard Group Inc. grew its stake in Dyne Therapeutics by 47.7% in the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after acquiring an additional 1,110,629 shares during the period. Finally, Victory Capital Management Inc. acquired a new position in Dyne Therapeutics in the 2nd quarter valued at $676,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Insider Activity at Dyne Therapeutics

In related news, COO Susanna Gatti High sold 8,976 shares of the stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total value of $308,864.16. Following the completion of the transaction, the chief operating officer now owns 131,636 shares of the company’s stock, valued at approximately $4,529,594.76. This represents a 6.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO John Cox acquired 32,000 shares of the company’s stock in a transaction on Wednesday, September 4th. The shares were acquired at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the acquisition, the chief executive officer now directly owns 8,000 shares in the company, valued at $264,320. The trade was a -133.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 176,257 shares of company stock worth $6,193,718. 20.77% of the stock is currently owned by company insiders.

Dyne Therapeutics Trading Up 6.5 %

Shares of DYN stock opened at $31.13 on Friday. The company has a market cap of $3.17 billion, a PE ratio of -8.74 and a beta of 1.10. The company’s fifty day simple moving average is $31.89 and its 200-day simple moving average is $35.39. Dyne Therapeutics, Inc. has a 52 week low of $10.12 and a 52 week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Equities research analysts expect that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on DYN shares. Morgan Stanley lifted their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Piper Sandler reaffirmed an “overweight” rating and set a $53.00 price objective on shares of Dyne Therapeutics in a research note on Monday, September 23rd. Royal Bank of Canada started coverage on shares of Dyne Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $45.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $50.82.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.